New product lines strengthen Bayer’s animal health business in the U.S.
Leverkusen, January 4, 2013 – Bayer HealthCare announced today that it has received the necessary regulatory approval from the Federal Trade Commission to complete the acquisition of the U.S.-based animal health business of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA). As announced in September 2012, Bayer will pay up to 145 million USD which includes an upfront payment of 60 million USD plus a total of 85 million USD in milestone payments, which are linked to the successful and timely achievement of manufacturing and sales targets. The transaction includes a manufacturing site in St. Joseph, Missouri and around 300 employees.
Favorable Performance Over 2011 Periods Continues
Hawthorne, New York, United States, Tuesday, February 05, 2013 -- (Business Wire India) –
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) ("Taro" or the "Company") today provided unaudited financial results for the three and nine month periods ended December 31, 2012.
Creates 3rd largest global generics company with presence in 60+ markets$8.0+ billion anticipated pro forma combined 2012 revenueCombined management structured to immediately maximize combination value
PARSIPPANY, N.J. – October 31, 2012 – Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has completed the acquisition of the Actavis Group for EUR4.25 billion. The combination creates the world’s third largest generic pharmaceutical company, with anticipated pro forma combined 2012 revenues in excess of $8 billion.
Bayer Submits VEGF Trap-Eye (aflibercept) for Treatment of Macular Edema Following Central Retinal Vein...
Berlin, January 7, 2013 – Bayer HealthCare today announced that Bayer Yakuhin, Ltd., Osaka, Japan, has submitted an application for marketing authorization for VEGF Trap-Eye (aflibercept solution for injection) for the treatment of macular edema following Central Retinal Vein Occlusion (CRVO) to the Ministry of Health, Labour and Welfare (MHLW) in Japan.
The submission of VEGF Trap-Eye for macular edema following CRVO is based on data from the Phase III COPERNICUS and GALILEO studies. In both studies, the primary efficacy endpoint was the proportion of patients who gained at least 15 letters – measured on the Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart – of Best Corrected Visual Acuity (BCVA) at 24 weeks compared to baseline on the ETDRS visual acuity charts. The VEGF Trap-Eye 2 milligrams monthly group was significantly superior to the sham control group for the primary endpoint. The effects were largely maintained in the follow-up phase until week 52.